Table 1.
Patient Characteristics | Genotyping | Driver* and Treatment Status | |||
---|---|---|---|---|---|
Any | Full | No Driver | Driver + Tx | Driver No Tx | |
Sex | n=904 | n=423 | n=337 | n=162 | n=74 |
Male | 416 (46) | 213 (50.4) | 176 (52.2) | 67 (41.4) | 34 (45.9) |
Female | 488 (54) | 210 (49.6) | 161 (47.8) | 95 (58.6) | 40 (54.1) |
Age at enrollment,mean (range) | 64 (22-90) | 64 (22-90) | 64 (34-90) | 61 (35-86) | 63 (22-90) |
Performance Status | |||||
0 | 247 (27.6) | 109 (25.8) | 77 (22.9) | 47 (29.2) | 21 (28.4) |
1 | 574 (64.1) | 273 (64.7) | 226 (67.3) | 105 (65.2) | 44 (59.5) |
2 | 74 (8.3) | 40 (9.5) | 33 (9.8) | 9 (5.6) | 9 (12.2) |
missing | 9 (1.0) | 1 (0.2) | 1 (0.3) | 1 (0.7) | 0 |
Cigarette smoking history | |||||
Never | 219(24.6) | 101 (24.1) | 45 (13.4) | 86 (53.4) | 22 (29.7) |
Former | 556 (62.5) | 274 (65.4) | 242 (72.2) | 69 (42.9) | 41 (55.4) |
Current | 115 (12.9) | 44 (10.5) | 48 (14.3) | 6 (3.7) | 11 (14.9) |
Missing | 14 (1.5) | 4 (1) | 2 (0.6) | 1 (0.7) | 0 |
Prior therapy | |||||
Surgery | 389 (43.9) | 175 (41.6) | 149 (44.3) | 49 (30.4) | 33 (45.2) |
Chest radiotherapy | 137 (15.5) | 55 (13.1) | 54 (16.2) | 14 (8.7) | 14 (18.9) |
Chemotherapy | 487 (61.6) | 223 (57.5) | 205 (65.7) | 81 (53.6) | 40 (59.7) |
Time from metastatic disease dx to enrollment, mean (years) | 0.31 | 0.3 | 0.34 | 0.28 | 0.31 |
Driver in this table refers to sensitizing EGFR, BRAF V600E, and ERBB2 mutation, ALK, ROS1, and RET rearrangement, and MET amplification.